Testing sublingual allergy tablets with tezepelumab for severe asthma
Treatments studied
Part of Ear, nose & throat, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests if adding house dust mite allergy tablets (Acarizax) to tezepelumab (Tezspire) helps adults with severe allergic asthma stay in control. It is for people who are still struggling with asthma despite current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old and followed by an allergy or lung specialist in France.
- You are allergic to house dust mites, confirmed by a blood test and skin prick test.
- You have severe asthma that is not well controlled (Asthma Control Test score <20) and have had at least 2 asthma attacks in the past year.
- You have never received a house dust mite allergy tablet or shot in the last 5 years.
- You are not pregnant, breastfeeding, or planning to become pregnant, and you use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called tezepelumab for people with severe asthma that is not well controlled with current treatments. It aims to see if adding this drug can reduce asthma attacks and improve symptoms.
This trial tests if a drug called Tezepelumab can help adults with asthma who visit the emergency room. It aims to reduce severe asthma attacks and improve breathing control.
This study looks at how well the drug tezepelumab works in treating allergic bronchopulmonary aspergillosis (ABPA), a lung condition caused by an allergic reaction to a common fungus. It may help reduce asthma symptoms and flare-ups in people with severe asthma related to ABPA.
This study tests whether a physical activity program can help people with severe asthma achieve better control and reduce flare-ups when added to a new treatment called tezepelumab.
This trial looks at whether people with severe asthma who are taking the biologic tezepelumab can safely reduce their use of inhaled corticosteroids (ICS). It aims to see if reducing or stopping ICS affects asthma symptoms or flare-ups.
This study tests if tezepelumab can help reduce severe asthma attacks in children ages 5 to 11. It compares the drug to a placebo (a dummy treatment) to see if it is safe and effective.
Hear when a new Severe Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.